Dexcom Archives - Page 10 of 14 - Medical Design Sourcing

Dexcom wins FDA brekathrough nod for use of its CGM in hospitals

Dexcom (NSDQ:DXCM) announced that it received FDA breakthrough device designation for the use of its CGM in the hospital setting.

The Dexcom continuous glucose monitor (CGM) uses a small, wearable sensor and transmitter to continuously measure and send glucose levels wirelessly to a smart device to provide real-time glucose data and eliminate the need for fingersticks. It also offers customizable alerts and alarms to make the patient aware of blood sugar levels and potentially avoid dangerous low and high blood sugar events.

Get the full story at our sister site, Drug Delivery Business News.

Dexcom touts data showing next-gen G7 CGM provides accurate glucose readings

[Image from Dexcom]Dexcom (NSDQ:DXCM) published study results that prove the accuracy offered by its next-generation G7 continuous glucose meter.

San Diego-based Dexcom, which expects to launch G7 soon ahead of what the company’s President and CEO Kevin Sayer said will be a year full of activity, conducted the study in adults with either type 1 or type 2 diabetes (on intensive insulin therapy or not).

Get the full story at our sister site, Drug Delivery Business News.

These medtech companies care a lot about research

[Image from Unsplash] They’re making glaucoma-treating stents, tumor-treating fields, coin-sized CGMs and more. Discover the medtech companies that spend the most on research as a percentage of revenue.

The list comes from our annual Big 100 report, which examines the world’s 100 largest medical device companies and ranks them by revenue. (Check out our full Big 100 report here.)

Medtech companies that have spent the most on R&D as a percentage of revenue have had much to boast about:

Glaukos’s iStent inject is an eye implant designed for cataract surgery to reduce intraocular pressure in adults with mild-to-moderate primary open-angle glaucoma. It was a Prix Galien USA Awards nominee last year. Novocure announced in September 2021 that the FDA had granted breakthrough designation for its NovoTTF-200T liver cancer treatment system. NovoTTF-200T system is a tumor treating fields (TTFields) delivery system for use in tandem with atezolizumab and be…

These medtech companies care a lot about research

[Image from Unsplash]

They’re making glaucoma-treating stents, tumor-treating fields, coin-sized CGMs and more. Discover the medtech companies that spend the most on research as a percentage of revenue.

The list comes from our annual Big 100 report, which examines the world’s 100 largest medical device companies and ranks them by revenue. (Check out our full Big 100 report here.)

Medtech companies that have spent the most on R&D as a percentage of revenue have had much to boast about:

Glaukos’s iStent inject is an eye implant designed for cataract surgery to reduce intraocular pressure in adults with mild-to-moderate primary open-angle glaucoma. It was a Prix Galien USA Awards nominee last year.

Novocure announced in September 2021 that the FDA had granted breakthrough designation for its NovoTTF-200T liver cancer treatment system. NovoTTF-200T system is a tumor treating field…

Ahead of G7 launch, Dexcom CEO plans for ‘more activity than we’ve ever seen’ in 2022

With a major product approval and launch in its sights, Dexcom prepares for a big year in 2022.

Across 2021, Dexcom (NSDQ:DXCM) took several steps forward.

The company touted its next-generation G7 continuous glucose monitor (CGM) and announced a major regulatory nod and partnership for real-time application programming interfaces (APIs), to list a couple.

As the new year gets underway, expectations for the coming year have been set even higher.

“2022 holds about more activity than we’ve ever seen in a given year,” Sayer told Drug Delivery Business News. “It’s going to be a year of many of the same activities, but some very big advances on the product front. And then, once we get the hardware platforms out there, we’re hopeful we can then start coming up with several software solutions that are going to be different than what we’ve had in the past. It’s going to be a fun year.”

Get the full story at our sister s…

Ahead of G7 launch, Dexcom CEO plans for ‘more activity than we’ve ever seen’ in 2022

With a major product approval and launch in its sights, Dexcom prepares for a big year in 2022.

Across 2021, Dexcom (NSDQ:DXCM) took several steps forward.

The company touted its next-generation G7 continuous glucose monitor (CGM) and announced a major regulatory nod and partnership for real-time application programming interfaces (APIs), to list a couple.

As the new year gets underway, expectations for the coming year have been set even higher.

“2022 holds about more activity than we’ve ever seen in a given year,” Sayer told Drug Delivery Business News. “It’s going to be a year of many of the same activities, but some very big advances on the product front. And then, once we get the hardware platforms out there, we’re hopeful we can then start coming up with several software solutions that are going to be different than what we’ve had in the past. It’s going to be a fun year.”

Get the full story at our sister s…

Our top medtech stories of 2021

Covering the medical device industry enables writers to report on a wide range of world-changing news – financial markets, the pandemic, and the global supply chain problems – while also centering on jaw-dropping technology that improve patient care.

You’ll hear all those issues covered in our editorial’s team summation of their Top Stories of 2021 recorded in our recent episode of the DeviceTalks Weekly Podcast.

The editors of our life sciences pages picked the stories that meant most to THEM in a very transformational year.

12 of medtech’s biggest personnel changes in 2021

As medtech companies continued to drive innovation throughout the past 12 months, a number of high-level executives led the way.

Some of those companies and those executives opted for major changes over the course of 2021, though, with some high-profile moves from medtech giant to medtech giant.

Here are some of the biggest personnel moves in the medtech space in 2021:

Get the full story at our sister site, Medical Design & Outsourcing.

Medtech’s biggest personnel changes in 2021

As medtech companies continued to drive innovation throughout the past 12 months, a number of high-level executives led the way.

Some of those companies and those executives opted for major changes over the course of 2021, though, with some high-profile moves from medtech giant to medtech giant.

Here are some of the biggest personnel moves in the medtech space in 2021:

1. Medtronic’s internal shuffle causes movement in every direction

At the end of 2020, Medtronic (NYSE:MDT) confirmed that it would reorganize its corporate structure, creating 20 operating units and expecting annual savings of up to $475 million in connection with the changes.

Amid all the change, a number of personnel moves both in and out of the company came over the course of 2021. Among the changes was the big move of Medtronic’s former President of Pelvic Health and Gastric Therapies Brooke Story, who departed to become the worldwide president of BD’s Integra…

How medtech fared in the first waves of the pandemic

[Photo by Martin Sanchez on Unsplash]Medtech industry revenue, research spending and employment declined in the first year of the COVID-19 pandemic, according to a Medical Design & Outsourcing analysis of financial data.

Total sales, R&D spending and employment for the world’s largest medical device companies declined in 2020 and early 2021, according to a Medical Design & Outsourcing analysis tallying the ongoing pandemic’s initial toll on the industry.

To compare performance before and during the pandemic, MDO used the financial data that we’ve historically gathered to rank our Big 100 companies in the last three years. The majority of these companies reported full-year results for 2020; others operate on a fiscal year and reported annual results in the first half of 2021.

Some companies are not in this year’s Big 100 but were included in the analysis because they were ranked in pre-pandemic years. The handful of companies that joined this yea…

How medtech fared in the first waves of the pandemic

[Photo by Martin Sanchez on Unsplash]

Medtech industry revenue, research spending and employment declined in the first year of the COVID-19 pandemic, according to a Medical Design & Outsourcing analysis of financial data.

Total sales, R&D spending and employment for the world’s largest medical device companies declined in 2020 and early 2021, according to a Medical Design & Outsourcing analysis tallying the ongoing pandemic’s initial toll on the industry.

To compare performance before and during the pandemic, MDO used the financial data that we’ve historically gathered to rank our Big 100 companies in the last three years. The majority of these companies reported full-year results for 2020; others operate on a fiscal year and reported annual results in the first half of 2021.

Some companies are not in this year’s Big 100 but were included in the analysis because they were ranked in pre…

How some diabetes tech companies are honoring National Diabetes Month

World Diabetes Day (Nov. 14) may have passed, but it remains National Diabetes Month through the end of November.

A number of companies developing some of the most intriguing innovations in diabetes care have also stepped forward this month to organize awareness-raising efforts for the metabolic disease.

Here are some steps a handful of diabetes technology developers have made to try and bring more attention to diabetes management:

Get the full story at our sister site, Drug Delivery Business News.